MAPT and supranuclear palsy, progressive, 1: Most studies so far focused on the differential diagnosis between PSP and other parkinsonian syndromes, and several imaging biomarkers have been reported to distinguish PSP-RS from PD and multiple system atrophy, including planimetric MRI measures (manual or automated) [17–20], brain volumetry [21, 22], diffusion tensor imaging metrics [23–25], and PET imaging with 18FDG [26] or tau tracers [27].